KZR-540 IS A NOVEL ORAL SMALL MOLECULE INHIBITOR OF SEC61 COTRANSLATIONAL TRANSLOCATION THAT POTENTLY AND SELECTIVELY BLOCKS PD-1 EXPRESSION

被引：0

|

作者：

Delgado-Martin, Cristina ^{[1
]}

Anand, Neel ^{[1
]}

Anderl, Janet ^{[1
]}

Dong, Chengguo ^{[1
]}

Fan, Andrea ^{[1
]}

Fang, Ying ^{[1
]}

Kirk, Christopher ^{[1
]}

Muchamuel, Tony ^{[1
]}

Qian, Yu ^{[1
]}

Wang, Jinhai ^{[1
]}

Whang, Jennifer ^{[1
]}

Zuno-Mitchell, Patricia ^{[1
]}

机构：

[1] Kezar Life Sci, San Francisco, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0422

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

422

引用

收藏

页码：A443 / A443

页数：1

相关论文

共 2 条

[1] Sec61 inhibitor KZR-834, an anti-cancer agent, exhibits immunomodulatory activity and combines with PD-1 blockade to further enhance immune responses.
Whang, Jennifer A.
Fan, Andrea
Jiang, Jing
Kirk, Christopher J.
Muchamuel, Tony
CANCER RESEARCH, 2022, 82 (12)
[2] Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.
Lee, James J.
Powderly, John D.
Patel, Manish R.
Brody, Joshua
Hamilton, Erika Paige
Infante, Jeffrey R.
Falchook, Gerald Steven
Wang, HongWei
Adams, Lisa
Gong, Lucy
Ma, Anna W.
Wyant, Timothy
Lazorchak, Adam
Agarwal, Shefali
Tuck, David P.
Daud, Adil
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35